English
Introduction/Overview
NT-proBNP is a biomarker commonly evaluated in the assessment of patients with suspected acute heart failure (HF). However, diagnosing HF in patients with chronic kidney disease (CKD) is challenging due to the impact of reduced renal function on NT-proBNP levels. The PRECISE-HF study prospectively enrolled emergency department patients across 17 U.S. sites to evaluate novel age-stratified NT-proBNP cut points in CKD patients (eGFR <60 mL/min/1.73m²) and to assess their impact to diagnostic performance and prognostic outcomes.*
Key Study Findings
- Specificity: Diagnostic specificity maintained at 74% versus 72% using traditional cut points
- Sensitivity: Overall sensitivity of 82.1% with overlapping confidence intervals (78.7 – 85.1%) versus traditional cut points (81.8 – 91.1%)
- Accuracy (AUC): 0.88 for <50 years, 0.87 for 50–75 years, 0.83 for >75 years
- Prognostic Impact: Higher 90-day major adverse events (MACE; e.g., death, MI, stroke) in patients with NT-proBNP ≥ age-stratified cut points (log rank P < 0.01)
At a Glance
| Metric | Value |
| Sensitivity (All CKD) | 82.1% |
| Specificity (All CKD) | 74.2% |
| Positive Predictive Value | 78.1% |
| Negative Predictive Value | 78.7% |
Conclusion
Adjusting NT-proBNP rule-in thresholds for CKD patients was associated with preserved diagnostic accuracy and prognostic association in this high-risk population.
Learn More/Resources
Full study poster: Click here
Access NT-proBNP assay product information: Click here
*Disclaimer: Study findings are presented for scientific discussion only and do not modify or expand intended use of an assay as described in the Instruction For Use.
2026-15123
